Integrin-linked Kinase Expression Increases with Prostate Tumor Grade 1

J. Graff,J. Deddens,B. Konicek,B. Colligan,B. Hurst,H. Carter,J. H. Carter

Abstract:Purpose: Integrin-linked kinase (ILK) overexpression can suppress anoikis, promote anchorage-independent cell cycle progression, and induce tumorigenesis and invasion. Inhibition of ILK in prostatic adenocarcinoma (CaP) cells elicits cell cycle arrest and induces apoptosis. Furthermore, ILK expression increases with androgen-independent progression of human CaP cell lines, suggesting that increased ILK expression may be associated with CaP progression. Experimental Design:To assess whether ILK expression may be related to CaP development and/or progression, we have evaluated ILK expression by immunohistochemistry in 100 human prostate tissues. Results:We show that ILK expression increases significantly with CaP progression. ILK immunostaining is specifically increased in high-grade, primary human CaP relative to adjacent benign prostatic hyperplasia ( P < 0.001), benign prostatic hyperplasia from patients without cancer (P < 0.002), and low-grade CaP ( P 5 0.003). ILK overexpression is specifically associated with the increased proliferative index (P 5 0.001) that typifies CaP progression. Strikingly, intense uniform ILK immunostaining was inversely related to 5-year patient survival (P 5 0.004). Conclusions: ILK expression increases dramatically with CaP progression. ILK expression is also specifically related to the disproportionately increased proliferative index that contributes to the net gain of CaP cells during progression. Finally, enhanced ILK expression is inversely related to 5-year patient survival. These data therefore implicate increased ILK expression in prostate tumor progression. INTRODUCTION ILK 3 interacts with theb1 andb3 integrins and is activated by cell-extracellular matrix interactions (1, 2). ILK overexpression in epithelial cells suppresses anoikis and elicits anchorageindependent cell cycle progression (1–3), tumorigenesis, and tumor invasiveness (1, 4). Recent studies have indicated that ILK facilitates the phosphorylation of AKT at Ser , which is required for AKT activation (1, 5, 6). By regulating the activity of AKT as well as glycogen synthase kinase 3 (1, 5), ILK facilitates the assembly and activity of the b-catenin/LEF-1 transcription complex (1, 4), enhances cyclin D1 expression and CDK activity (1, 3), and suppresses expression of the invasion suppressor E-cadherin (1, 4, 7). Recent reports have suggested that ILK may be involved in prostate tumorigenesis and progression. Inhibition of ILK in CaP cell lines suppresses AKT activation, induces cell cycle arrest, and elicits apoptosis (8). Furthermore, we have recently shown that ILK expression increases in androgen-independent human CaP cells and xenografts derived from the androgendependent CaP cell line LNCaP (9). Although these reports implicate ILK in experimental models of human prostate cancer, there are currently no data regarding ILK expression in primary human CaPs. To assess whether ILK might be involved in CaP development and/or progression, we have evaluated ILK expression by immunohistochemistry in 100 primary prostate tissues. Our data reveal that ILK expression was significantly increased in the highest grade CaPs compared with BPH from patients without cancer, BPH adjacent to CaP, and low-grade CaP. Moreover, 81% of patients whose tumors overexpressed ILK failed to survive for 5 years. Together, these data implicate increased ILK expression in human prostate tumor progression. MATERIALS AND METHODS Prostate Tissue Collection. Archival, formalin-fixed, paraffin-embedded surgical specimens of BPH and CaPs were obtained from St. Elizabeth Medical Center (Covington/Edgewood, KY). Surgical consultation reports and clinical follow-up information were available for all prostate specimens and cancer patients. This study had the approval of the Institutional Review Board of St. Elizabeth Medical Center. A H&E-stained section from each block of prostate tissue studied was reviewed by a board-certified pathologist (H. W. C.) and graded according to the Mostofi grading system (10). According to this grading system, M1 represents well-differentiated CaP, M2 represents Received 1/18/01; revised 3/29/01; accepted 4/16/01. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisementin accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 This work is dedicated to the memory of Dr. Harry W. Carter. 2 To whom requests for reprints should be addressed, at Lilly Research Labs, Cancer Research Division, Eli Lilly and Company, Lilly Corporate Center, DC 0546, Indianapolis, IN 46285. Phone: (317) 277-0220; Fax: (317) 277-3652; E-mail: graff_jeremy@lilly.com. 3 The abbreviations used are: ILK, integrin-linked kinase; CaP, prostatic adenocarcinoma; BPH, benign prostatic hyperplasia; TUNEL, terminal deoxynucleotidyl transferase-mediated nick end labeling. 1987 Vol. 7, 1987–1991, July 2001 Clinical Cancer Research Research. on October 24, 2017. © 2001 American Association for Cancer clincancerres.aacrjournals.org Downloaded from moderately differentiated CaP, and M3 represents poorly differentiated CaP (10). Samples designated M1 1M2 and those designated M21M3 were heterogeneous, with both tissue patterns present. The Mostofi grades assigned correspond to Gleason grades as follows. The M1 grade for well-differentiated tumors corresponds to Gleason grades 1 and 2. The M2 grade tumors correspond to tumors of Gleason grade 3. High-grade, poorly differentiated M3 tumors correspond to the least-differentiated Gleason grade 4 and 5 tumors (11). Immunohistochemistry. Antibody staining was performed on 5-mm histological sections of formalin-fixed, paraffin-embedded surgical specimens. All sections were deparaffinized in Hemo-De (Fisher, Pittsburgh, PA) and rehydrated through a graded series of alcohols before antigen retrieval (DakoTarget Retrieval Solution; DAKO Corp., Carpinteria, CA). After incubation with 0.3% peroxide in methanol and incubation with normal blocking serum, sections were incubated with primary anti-ILK antibody (0.2mg/ml; Upstate Biotechnology, Lake Placid, NY) at 4°C overnight. Immunodetection was performed with the Vectastain ABC rabbit IgG kit (Vector Laboratories, Burlingame, CA) using diaminobenzidine as the chromogen. Positive controls for ILK immunostaining were formalin-fixed, paraffin-embedded human prostate cancer xenografts previously shown to be high expressors of ILK by Western blot analysis (LNCaP and LNAI; Ref. 9) and human placenta, the tissue from which ILK was initially cloned (Ref. 2; data not shown). Negative controls included CaP sections stained without antibody (data not shown) and sections stained first with nonspecific rabbit IgG at the same protein concentration as the primary anti-ILK antibody, followed by horseradish peroxidase-linked antirabbit secondary antibody (Fig. 1 A). All sections were counterstained with Gill’s hematoxylin. Evaluation of Immunohistochemical Stain. Staining patterns including tissue distribution (epithelial/stromal), extent Fig. 1 ILK immunostaining of BPH and CaP. Representative immunostained sections are shown. A represents a highgrade CaP (the same as that shown inH) stained with rabbit IgG followed by antirabbit secondary antibody as a negative control for staining.B depicts a typical stain of BPH from a noncancer patient with little to no staining.C shows BPH adjacent to the M11M2 tumor in D. E depicts BPH adjacent to the high-grade M21M3 tumor in F. G represents a M3 tumor, whereasH shows a high-grade M21M3 tumor. Note the intense, uniform staining in the high-grade CaPs (F–H) in contrast to the focal staining characteristic of the low-grade CaPs (D). Black bar in B, 100 mM. 1988ILK Expression Increases with Prostate Tumor Progression Research. on October 24, 2017. © 2001 American Association for Cancer clincancerres.aacrjournals.org Downloaded from of stain, and stain intensity were evaluated for each specimen by two experienced investigators [H. W. C. (a board-certified pathologist) and J. H. C.]. In specimens with CaP, the staining pattern was noted for both the neoplasm and the adjacent BPH tissue. The evaluation was categorical, and staining was classified as negative (,10% of the epithelium stained), focal (heterogeneously positive with less than 50% of the epithelium stained in the vast majority of cases), or uniformly positive (involving more than 90% of the epithelium). Assessment of Proliferation and Apoptosis. Proliferative index was assessed by immunostaining with mouse monoclonal antibody to Ki-67 [2mg/ml; Oncogene Research Products, Cambridge, MA (12)] after antigen retrieval for 5 min in a microwave oven in 0.1M citrate buffer (pH 6.0). Ki-67 positivity was detected with the Vectastain ABC mouse IgG kit (Vector Laboratories). These sections were counterstained with methyl green. An average number of 2618 6 197 cells was counted per section for Ki-67 positivity to determine the percentage of cells undergoing proliferation. Apoptotic index was assessed by TUNEL staining (13). To assess the percentage of cells undergoing apoptosis, an average of 3809 6 284 cells was counted per section for terminal deoxynucleotidyl transferase positivity. The proliferative or apoptotic index was then calculated by the following equation: (number of stained nuclei:total number of nuclei counted) 3 100%. Statistical Analyses. All statistical analyses were performed with the SAS program (SAS, Cary, NC). For statistical analyses, tissues were divided into five groups: ( a) group A, high-grade CaP (M3 and M21M3); (b) group B, low-grade CaP (M2, M11M2, and M1); (c) group C, BPH adjacent to highgrade CaP (i.e., group A); (d) group D, BPH adjacent to lowgrade CaP (i.e., group B); and (e) group E, BPH from patients without cancer. For all statistical analyses, staining patterns compared were negative/focal versus uniform. Relationships between staining patterns and each t